Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses
| Autor: | E. I. Samokhvalov, Alexander L. Gintsburg, Andrei N. Vzorov, V. V. Chebanenko, D. V. Scheblyakov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Env
viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enveloped RNA viruses haemagglutinin Biophysics Reviews Biology spike protein medicine.disease_cause Immune system Viral envelope Structural Biology Influenza A virus medicine Humans influenza A virus neutralizing antibodies fusion mechanisms SARS-CoV-2 Host (biology) COVID-19 RNA Spike Protein vaccines Antibodies Neutralizing Virology Spike Glycoprotein Coronavirus HIV-1 biology.protein Antibody |
| Zdroj: | Molecular Biology |
| ISSN: | 1608-3245 0026-8933 |
| Popis: | Abstract— Most vaccines work by inducing neutralizing antibodies that target the viral envelope. Enveloped RNA viruses have evolved mechanisms for surface glycoproteins to evade host immune responses, which exhibit substantial variability, even among different strains. Natural infection and vaccines using native forms of surface proteins may induce broadly neutralizing antibodies, yet with low and ineffective levels. Class I membrane-fusion proteins of enveloped RNA viruses, HIV-1, influenza A virus, SARS-CoV-2, yield a stable conformation (so-called “pre-fusion”) in providing fusion between viral and host cell membranes. Modified viral surface proteins that are based on these features induce neutralizing antibodies with activity available against a broad spectrum of circulating strains and make it possible to overcome the difficulties associated with escape/variability of viral antigen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink